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Objectives: We report single-institution clinical efficacy and safety outcomes for patients with
unresectable locally advanced cholangiocarcinoma who were treated with stereotactic body
radiation therapy (SBRT) and a subset of patients who received neoadjuvant SBRT and
chemotherapy as part of an orthotopic liver transplantation (OLT) protocol.
Methods and materials: From October 2008 to June 2015, 31 consecutive patients with unre-
sectable extrahepatic (n Z 25) or intrahepatic (n Z 6) cholangiocarcinoma were treated with
SBRT and retrospectively analyzed. Four patients underwent liver transplantation, and 1 underwent
resection. SBRT was delivered in 5 fractions with a median dose of 40 Gy. Toxicity was scored
using the Common Terminology Criteria for Adverse Events Version 4.0. Overall survival (OS),
time to progression, and local control were estimated using the Kaplan-Meier method.
Results: The median follow-up time was 11.5 months. The 1- and 2-year OS rates were 59% and
33%, respectively, with a median survival of 15.7 months. The 1- and 2-year freedom from
progression was 67% and 34%, respectively. Median time to progression was 16.8 months. Nine
patients had local failure. The actuarial 1- and 2-year local control rates were 78% and 47%,
respectively. Among patients who also had OLT, the median OS was 31.3 months. Twenty-four
patients (77%) experienced some form of acute grade 1-2 toxicity, most commonly fatigue or pain.
Five patients (16%) experienced grade 3 toxicity.Conflicts of interest: None.
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angiocarcinoma either as a component of neoadjuvant therapy prior to OLT or as part of definitive
therapy for patients who are unresectable and not eligible for transplantation.
Copyright ª 2016 the Authors. Published by Elsevier Inc. on behalf of the American Society for
Radiation Oncology. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Cholangiocarcinoma is a malignancy of the biliary
duct epithelium and is typically classified as either
intrahepatic or extrahepatic. Klatskin tumors arise at
the bifurcation of the common bile duct and repre-
sent approximately 50% of cases.1 Chol-
angiocarcinoma is uncommon, but there is some
evidence that its incidence has been increasing over
the past few decades.2 Prognosis is generally poor;
however, it is improved in patients who can undergo
surgical resection. Unfortunately, few patients are
candidates for resection at the time of presentation.3
Treatment for unresectable or recurrent disease typi-
cally focuses on palliation with an overall survival
(OS) less than 10% at 5 years and a median survival
of approximately 7 months.4
Definitive radiation therapy, with or without chemo-
therapy, improves the median survival of patients who are
unresectable from 2 to 4 months to 9 to 12 months.5,6
Even with locoregional radiation therapy, local recur-
rence is commonly the first site of progression, and
mortality is often associated with the consequences of
local tumor growth. This has led to an interest in
improving local control by escalating radiation therapy
doses both with brachytherapy7 and SBRT, both with
encouraging results.
A retrospective series from Mayo Clinic reported 10
patients with unresectable primary or recurrent
cholangiocarcinoma who underwent stereotactic body
radiation therapy (SBRT) using a median dose of 55
Gy.8 This study demonstrated 100% local control at a
median follow-up of 14 months, but unfortunately, the
toxicity was high. Recent retrospective data from MD
Anderson demonstrated a dose-dependent improvement
in local control and OS9 when radiation therapy was
delivered with a biologic effective dose of >80.5, which
compared favorably with surgical resection. The toxicity
profile in this study was favorable; however, the majority
of patients had intrahepatic disease. Very few data are
available on the use of SBRT in the treatment of patients
with unresectable extrahepatic cholangiocarcinoma.
Therefore, we sought to understand our institutional
clinical outcomes utilizing SBRT and chemotherapy,
both neoadjuvantly prior to orthotopic liver transplant
(OLT) and definitively in patients who were not eligible
for OLT.Methods and materials
Patients and follow-up
Thirty-one patients with cholangiocarcinoma who un-
derwent SBRT between October 2008 and June 2015
were included in the study. Our institutional review board
approved the study, and retrospectively acquired data
were de-identified in accordance with Health Insurance
Portability and Accountability Act of 1996 guidelines. A
subset of patients was part of a single-institution pro-
spective study to evaluate the use of neoadjuvant SBRT
with chemotherapy followed by OLT for patients with
unresectable or recurrent cholangiocarcinoma. Eighteen
of 31 patients were included in the study and evaluated
for transplant: 14 patients who were listed for and 4 pa-
tients who ultimately underwent OLT.Inclusion and exclusion criteria
Consecutive patients who were treated with SBRT for
either intrahepatic or hilar cholangiocarcinoma were
included. Patients were diagnosed by malignant stricture
on cholangiography or biopsy/cytology results that
demonstrate malignancy, cancer antigen (CA) 19-9 >100
U/mL, or aneuploidy. Patients were excluded from the
study if they had an uncontrolled infection, a lesion >8
cm on imaging scans, medical conditions or other ma-
lignancies that preclude liver transplantation, or extrahe-
patic malignancy. All patients underwent a complete
staging workup that typically consisted of positron
emission tomography (PET) with computed tomography
(CT) and magnetic resonance imaging (MRI). Patients
with locoregional nodal involvement were included in the
study if the location was adjacent to the primary tumor
and thus amenable to inclusion in the high-dose SBRT
volume group. All patients were treated and seen during
the follow-up period by the same radiation oncologist
(P.L.). All patients underwent a surgical staging operation
prior to OLT.SBRT treatment planning
All planning CT scans were obtained with a Siemens
SOMATOM Definition AS scanner (Siemens Healthcare
Table 1 Patient and treatment characteristics
Characteristic Number (%)
Patients 31
Target volume (cc)
Median 59.3
Range 13.8-174.5
Total dose (gray)
Median 40
Range 25-50
Number of fractions 5
Dose to planning target volume (gray)
Average maximum dose 42.60
Average mean dose 39.84
Average minimum dose 33.54
Chemotherapy received
Chemotherapy 23 (74)
No chemotherapy 8 (26)
Chemotherapy regimen
Gemcitabine/cisplatin 19 (83)
Gemcitabine alone 2 (9)
Gemcitabine/oxaliplatin 1 (4)
Capecitabine/oxaliplatin 1 (4)
Chemotherapy duration (weeks)
Median 23.7
Range 2.6-112
Age, y
Median 63
Range 32-94
Gender
Male 19 (61)
Female 12 (39)
Tumor Location
Intrahepatic 6 (19)
Extrahepatic 25 (81)
Treatment Location
Tumor alone 29 (94)
Tumor and portal node 2 (6)
Pertinent history
Inflammatory Bowel Disease 2 (6)
Chronic hepatitis 3 (10)
Hemochromatosis 1 (3)
Pretreatment cancer antigen 19-9
Average 1876
Range <1 to 23,000
Tumor size (cm)
Median 2.7
Range 1-7.3
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A 4-dimensional CT scan was performed under free-
breathing conditions. Images were acquired during the
portal venous phase. Data from PET-CT and/or MRI
scans with Eovist were incorporated in the target defini-
tion when available and helpful. For each case, the gross
tumor volume, normal liver, right and left kidneys, spinal
cord, esophagus, stomach, duodenum near the gross
tumor volume, and bowel bag were segmented. An
internal target volume was generated with the maximum-
intensity projection derived from the 4-dimensional CT
scan to derive the tumor’s motion envelope. The internal
target volume was then expanded to 5 to 8 mm to generate
a planning target volume (PTV).
The volume of normal liver (ie, total liver minus PTV)
receiving 15 Gy was maintained at <1000 mL, the spinal
cord and kidneys were limited to a maximum of 2.5 Gy
per fraction, the volumes of bowel bag and stomach
receiving 20 Gy were maintained at <20 mL. The volume
of duodenum receiving 20 Gy was kept at <9 mL, which
was adapted from research by Murphy et al.10 Our liver
constraint, which was more conservative than current
guidelines, was adapted using the principles outlined by
Schefter et al.11 The bowel and stomach constraints were
used per Rwigema et al12 in which patients with
abdominal and pelvic metastases were treated with SBRT
using these constraints with minimal small bowel and
stomach toxicity. With the single fraction constraint from
Murphy et al as a guide, we relaxed the constraint slightly
to account for a fractionated regimen but stay as conser-
vative as possible given the high rates of duodenal
toxicity in this patient population.
The biliary tree was not routinely segmented. Biliary
toxicity in this patient population is an area of ongoing
research, and some studies show acceptable levels of
biliary toxicity with a dose of 40 Gy in 5 fractions.13
Additionally, many of our patients had biliary stents
placed prior to radiation, which was thought to potentially
mitigate biliary tree fibrosis and stenosis due to the disease
or radiation. SBRT was delivered in 5 fractions, typically
every other day, with total doses ranging from 25 to 50 Gy.
Nearly all patients (26 of 31) received a total dose of 40 Gy
in 5 fractions. All patients who proceeded to treatment with
surgery underwent 40 Gy in 5 fractions. Two patients had
involved portal nodes, which were included in the SBRT
treatment volume. Patients who received treatment earlier
in the study were treated with a lower dose (25-30 Gy in 5
fractions) when we had less experience with the technique
and were more cautious. One patient received 50 Gy in 5
fractions. The reason for escalation of the dose in this
patient was young age (30s), ineligibility for liver trans-
plantation, and our ability to safely meet constraints at the
higher dose. The PTV was normalized and plans were
designed such that 95% of the PTV received the full pre-
scription dose (Table 1). The average maximum dose
(Dmax) was 111% of the prescribed dose (range, 98-118%).The average mean dose to the PTV was 104% of the
prescribed dose (range, 91-107%).Statistical analysis
Follow-up time was calculated from the last day of
radiation therapy to either the last date of contact or death.
Local progression and OS were calculated from the last
day of radiation therapy to the date of local progression
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disease on imaging was defined using Response Evalua-
tion Criteria in Solid Tumors (RECIST) Version 1.1 if
applicable, or as increase in fluorodeoxyglucose (FDG)
avidity on PET compared with fluorodeoxyglucose prior
to SBRT. The Kaplan-Meier method was used to ascer-
tain the 1- and 2-year OS, local progression, and freedom-
from-progression rates as well as the median survival
times. The survival plots were generated using the
Kaplan-Meier method. Analysis was performed using
SAS Version 9.4 (SAS Institute, NC).
Results
Baseline patient and disease-specific characteristics are
described in Table 1. Thirty-one consecutive cases of
unresectable cholangiocarcinoma treated with SBRT be-
tween October 2008 and June 2015 were analyzed. The
median patient age at diagnosis was 63 years. Three pa-
tients had a history of chronic viral hepatitis, 2 patients had
inflammatory bowel disease, and 1 patient had hemochro-
matosis. Four cases were recurrent; of these, two received
prior chemoradiotherapy initially. Of these 2 cases, both
received 54 Gy previously. One patient had undergone a
Whipple procedure alone and another a Whipple procedure
followed by adjuvant chemotherapy. The median post-
treatment follow-up time ranged from 1 to 44 months
with a median follow-up time of 11.5 months. One patient
had resection after SBRT, and 4 had OLT.
Local control
In total, 9 patients suffered a local recurrence. Of note,
one of these 9 patients had disease progression after
transplant at the site of the porta hepatis. The remainder of
the local recurrences were in patients who were treated
nonsurgically. All local recurrences were in the high-dose
SBRT field. The actuarial local control rate was 78% at 1
year and 47% at 2 years (Fig 1). Of the patients whoFigure 1 Kaplan-Meier curve demonstrating time to local
tumor progression.underwent liver transplant or resection (n Z 5), all had a
favorable tumor response to SBRT at the time of OLT.
Most commonly, the pathology from the ex-plant showed
extensive radiation fibrosis with small and intermediate
vascular radiation changes. Negative margins were ach-
ieved in all surgeries, including that for the patient who
underwent resection instead of OLT. Pathologic features
are summarized in Table 2.
Survival and progression
The 1- and 2-year OS rates were 59% and 33%,
respectively, with a median survival of 15.7 months
(Fig 2). The 1- and 2-year freedom-from-progression rates
were 67% and 34% respectively. The overall median time
to progression was 16.8 months. Of the patients who
underwent OLT, one died 18 weeks after transplantation,
one survived 30 months after transplantation, and 2 others
were still alive at the time of the last follow-up (11 and 15
months from transplant). The patient who underwent
resection (of liver segments 4B and 5) was alive at the
time of the last follow-up (28 months after resection). Of
the patients who underwent any type of surgery, median
OS by Kaplan-Meier method was 31.3 months (Table 2).
For patients who were treated nonsurgically, median OS
was 12.7 months. Two patients progressed regionally,
including one patient who had an intrahepatic failure out
of the SBRT field and one patient who had a regional
recurrence in a periportal lymph node. One patient pro-
gressed both regionally and distantly to the liver and
retroperitoneal lymph nodes. Two patients progressed
distantly with metastases to lung and ureter, respectively.
Toxicity
Twenty-four patients (77%) experienced some form of
acute grade 1-2 toxicity from SBRT based on Common
Terminology Criteria for Adverse Events Version 4.0.
with mild fatigue or abdominal pain being the most
common. One patient developed grade 3 duodenal
obstruction acutely 2 months after radiation. Five patients
(16%) experienced severe late toxicity, of whom 2
developed grade 3 duodenal obstruction, 2 experienced
grade 3 duodenal hemorrhage, and 1 had grade 4
duodenal hemorrhage. One patient also had long-term
abdominal pain (Table 3).
All patients who experienced severe late toxicity were
prescribed a dose of 40 Gy in 5 fractions. Of the 5 pa-
tients, 3 had maximum duodenal doses of >40 Gy and 2
had maximum doses of 33.5 Gy and 3 Gy.
Discussion
Patients with unresectable cholangiocarcinoma typi-
cally have a very poor prognosis of 7 to 12 months when
Table 2 Treatment and outcomes of surgical patients
Patient
Number
Neoadjuvant Treatment/Date
of completion
Date of surgery
(months post-SBRT)
Pathologic findings Outcome (months post-SBRT)
1 SBRT followed by chemo,
3/17/10
1 month (OLT) Extensive fibrosis, þresidual
carcinoma
Death 6 months
2 SBRT alone, 12/21/09 5 months (OLT) Residual carcinoma Local progression 19.5
months, death 33.5 months
3 SBRT followed by chemo,
9/24/12
5.5 months (resection) No residual carcinoma Alive at last follow-up at 33.5
months
4 SBRT followed by chemo,
8/16/13
18 months (OLT) Extensive fibrosis, no residual
carcinoma
Alive at last follow-up at 28.5
months
5 SBRT followed by chemo,
4/21/14
6 months (OLT) Extensive fibrosis, þresidual
carcinoma
Alive at last follow-up at 20
months
SBRT, stereotactic body radiation therapy; OLT, orthotopic liver transplantation.
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chemotherapy, often with a palliative intent. Metastatic
disease is uncommon, and survival is usually dictated by
local progression.14,15
A small series of patients with unresectable chol-
angiocarcinoma who were treated with SBRT have shown
promising rates of local control but with variable
toxicity.8,16,17 In one of the earliest published series,
Kopek et al described the results of 27 patients with
unresectable cholangiocarcinoma (26 of 27 patients with
Klatskin type) who were treated with 45 Gy in 3 frac-
tions.16 The patients showed a median progression-free
survival of 6.7 months and OS of 10.6 months. Local
control was excellent, and only 2 patients failed locally
with an actuarial 1-year local control rate of 84%. How-
ever, gastrointestinal toxicity was high (30%), with 6
patients developing severe duodenal ulceration and 3
developing duodenal stenosis. Of note, the treatment
margins in this series were rather large (5 mm radially and
10 mm cranial-caudal) compared with the commonly used
5 mm in all directions.
Three subsequent studies evaluated similar regimens.
The first used a dose of 30 Gy in 3 fractions in a series
of 10 patients, all of whom were diagnosed with a KlatskinFigure 2 Kaplan-Meier curve demonstrating overall survival,
stratified by surgical and nonsurgical patients.tumor.18 The study reported a high local failure rate with
6 of 10 patients experiencing a local progression. The
median OS was 35.5 months in this cohort. The authors
did not report any grade 3 or 4 toxicities. The lower
dose may explain both the decreased toxicity and the
high rate of local progression. In the Mayo Clinic series,
the doses ranged from 45 to 60 Gy in 3 to 5 fractions.8
The study reported a 12-month OS of 73%. Two patients
(20%) in that study had severe late toxicity, including 1
patient with grade 3 biliary stenosis and 1 patient with
grade 5 liver failure. Similar to the patients in our study,
treatment margins of approximately 5 mm were used.
The third study was a larger series that was published in
2014 and included 58 patients (half with primary tumors
and half with recurrent disease) who were treated with
SBRT.19 The rates of local control at 1- and 2-year
follow-up were 85% and 72%, respectively. The 1-
and 2-year OS rates were 53% and 28%, respectively,
with a median OS of 13 months. The study reported
only 6 patients (10%) with grade 3 toxicity. It is
important to note that the vast majority of patients in this
series had intrahepatic disease. Intrahepatic tumors tend
to result in lower rates of high-grade toxicity (<10%) as
reported in series of patients with hepatocellular carci-
noma treated with SBRT20,21 due to a favorable locationTable 3 Toxicity
Toxicity Number (%)
Acute (<3 months post-RT)
Fatigue 11 (35)
Pain 7 (23)
Nausea 3 (10)
Duodenal obstruction 1 (3)
Other 3 (10)
Late (>3 months post-RT)
Duodenal ulcer (Gr 3) 2 (6)
Duodenal ulcer (Gr 4) 1 (3)
Duodenal obstruction (Gr 3) 2 (6)
RT, radiation therapy.
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stomach, duodenum, and jejunum. Also of note, the
treatment margins were smaller in this series at 2 mm
radially and 4 mm cranial-caudal.
Given the high rates of duodenal toxicity in this patient
population, it is worthwhile to compare the results with
SBRT in patients with pancreatic cancer because the
pancreas is also an organ that is intimately associated with
the duodenum. Herman et al conducted a phase 2 multi-
institutional trial to evaluate SBRT (33 Gy in 5 fractions)
after gemcitabine in patients with unresectable pancreas
adenocarcinoma.22 In that series, the researchers observed
6 cases of severe late toxicity (13%). Three patients had
grade 3 ulceration, one had grade 4 fistula, one died due to
gastrointestinal bleeding from direct tumor extension into
the duodenum, and one died due to secondary bleeding
from stent migration. These rates of toxicity are similar to
those in our study, again emphasizing the challenges of
minimizing toxicity when delivering SBRT close to the
duodenum.
In our current study, we observed a median OS of 12.7
months among patients who did not undergo OLT. Nine
of 31 patients experienced local progression with a 1-year
actuarial local control rate of 78%, which compares very
favorably with other series that report outcomes for
extrahepatic disease when balanced against high risk for
toxicity in treating at this location. Specifically, we
observed 5 of 31 patients (16%) with late grade 3
toxicity, 3 with duodenal ulcer and 2 with duodenal
strictures. When comparing this percentage with the doses
and toxicity rates cited above, we feel this is an acceptable
toxicity especially given the patients’ overall poor prog-
nosis and lack of treatment options. Efforts towards
reducing duodenal toxicity are ongoing and may be ach-
ieved with using techniques that offer more compact
dosimetry, better image-guidance techniques, or other
means. Duodenal toxicity is not well understood and re-
mains a subject of ongoing investigation. Indeed, 2 of our
patients who had severe late toxicity had modest or very
small doses to the duodenum, suggesting that other fac-
tors such as the possibility of severe toxicity that results
from damage to the biliary tree, which is often under-
reported, may be contributing.
Excellent outcomes have been reported for patients
with unresectable cholangiocarcinoma who undergo
neoadjuvant chemoradiation followed by OLT with up to
70% recurrence-free survival at 5 years.23,24 A series of
132 patients with cholangiocarcinoma conducted at
UCLA25 showed improved recurrence-free survival in
patients who underwent OLT versus patients in the
resection group (33% vs 0% at 5 years). Among patients
who underwent transplants, survival rates were improved
for those patients who received neoadjuvant and adjuvant
therapy versus adjuvant alone or no additional therapy. In
the current study, we showed very favorable rates of
survival in patients who underwent transplants with amedian OS of 31.3 months. However, the numbers are
very small and definitive conclusions cannot be made.
Limitations
Our study has several limitations, including a retro-
spective study design, small sample size, and relatively
limited follow-up time of approximately 1 year. However,
cholangiocarcinoma is a relatively rare and rapidly fatal
disease; therefore, a 1-year median follow-up does pro-
vide meaningful results, especially since many patients
were enrolled in a prospective clinical trial with good
follow up.
Conclusions
To our knowledge, this is the largest report on patients
with primarily extrahepatic cholangiocarcinoma who
were treated with SBRT. Our local control and OS
compare favorably with those reported in the literature,
especially when considering that many of the published
series are small and include patients with primarily
intrahepatic cholangiocarcinoma. This technique appears
to have good primary tumor control that is comparable to
other dose-escalation methods. Using SBRT before
transplant or resection appears to offer a high survival rate
in a limited number of eligible patients and may be
potentially curative. More patients and longer follow up
time is necessary to validate these results. Importantly,
significant grade 3 or higher toxicity persists and typically
includes duodenal ulcers or obstruction. In the future,
more advanced image-guided approaches such as MRI-
guidance and tracking coupled with adaptive radiation
therapy may further improve local tumor control with
SBRT and decrease late toxicity in this patient population.
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